A Phase II Trial of Intermediate Radiation Dose For Lymphoma

Official Title

A Phase II Trial of Intermediate Radiation Dose For Low Grade Follicular Lymphoma


The purpose of this study is to determine the optimal radiation dose fractionation regimen for low grade follicular lymphoma.

It is hypothesized that the complete response rate with the use of 12 Gy in 6 daily fractions is 80% (10% total width of the confidence interval) at 3 months.

This phase II study will evaluate whether an intermediate dose for follicular lymphoma is associated with excellent response rates while minimizing acute and late toxicity.

Trial Description

Primary Outcome:

  • Complete response within the radiated volume at 1month post radiation
Secondary Outcome:
  • Overall survival, progression-free survival and toxicity

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society